Background: Proton pump inhibitors (PPIs) are indicated for many gastric disorders, but reports of potentially inappropriate prescribing are widespread. Serious adverse effects of long term PPI therapy, including increased risk of fracture, Clostridium difficile infection and hypomagnesaemia continue to cause concern, particularly in older persons. The aim of this study was to explore possible reasons for potentially inappropriate prescribing (PIP) of PPIs. Methods: This was a qualitative study. 23 doctors were issued an online survey, exploring topics such as: familiarity with licensed PPI indications and associated doses/duration of treatment, potential adverse effects and current PPI prescribing practices.
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Results: Survey response rate was 52% (12 respondents). Long term PPI therapy was selected for inappropriate indications, such as Los Angeles Grade A oesophagitis. The adverse effects most recognised were: hypomagnesaemia (83%), Clostridium difficile infection (67%) and increased fracture risk (58%). Knowledge of potential drug-drug interactions was low, except for clopidogrel (92%). Only 33% of the opportunities for prescription review were selected, with admission cited as the optimum time for review. Documentation of indication for newly prescribed PPIs on discharge was low (25%), but duration of therapy was higher (58%), particularly if noted on oesophago-gastroduodenoscopy (OGD) reports. Conclusions: PPIs were perceived as very safe, but knowledge of recommended treatment durations, awareness of potential adverse effects and drug-drug interactions were low. Review of PPI prescriptions was infrequent. Documentation of indication for newly prescribed PPI on discharge was low, but documentation of duration was higher, Education initiatives and modification of OGD reports to capture additional prescribing information are possible interventions. Reference 1. Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Digestive Diseases and Sciences 2015; 60: 2280-6. iii13
